Profile data is unavailable for this security.
About the company
CSPC Pharmaceutical Group Ltd is an investment holding company primarily engaged in the manufacture and sale of pharmaceutical products. The Company operates its business through three segments. The Finished Drugs segment in engaged in the research and development, manufacture and sale of pharmaceutical products and licensing business. The Bulk Products segment is engaged in the manufacture and sale of vitamin C, and antibiotic products in bulk powder form. The Functional Food and Others segment is engaged in the manufacture and sale of functional food products (including caffeine food additives, anhydrous glucose, acarbose and vitamin C buccal tablets), provision of healthcare service and others. The Company’s product therapeutic areas include nervous system, oncology, anti-infectives, cardiovascular, respiratory system, digestion and metabolism and others. The Company conducts its business in the domestic and overseas markets.
- Revenue in HKD (TTM)34.91bn
- Net income in HKD6.54bn
- Incorporated1992
- Employees20.30k
- LocationCSPC Pharmaceutical Group LtdNo. 226 Huanghe StreetSHIJIAZHUANG 050035ChinaCHN
- Phone+86 31 187037015
- Fax+86 31 187039608
- Websitehttps://www.cspc.com.hk/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| China Resources Pharmaceutical Group Ltd | 276.33bn | 4.16bn | 31.29bn | 72.76k | 7.51 | 0.5865 | 2.45 | 0.1132 | 0.6627 | 0.6627 | 43.98 | 8.49 | 0.966 | 6.09 | 3.00 | 3,786,016.00 | 3.19 | 3.02 | 12.13 | 11.35 | 15.78 | 15.72 | 3.31 | 2.87 | 1.12 | 11.50 | 0.4396 | 24.73 | 12.16 | 8.86 | 10.11 | 2.80 | 13.58 | 7.05 |
| CSPC Pharmaceutical Group Ltd | 34.91bn | 6.54bn | 59.18bn | 20.30k | 9.04 | 1.54 | 14.91 | 1.70 | 0.5517 | 0.5517 | 2.95 | 3.23 | 0.6914 | 3.01 | 4.99 | 1,485,554.00 | 13.25 | 16.08 | 17.64 | 21.57 | 71.38 | 72.95 | 19.16 | 19.63 | 2.22 | 40.86 | 0.0106 | 35.51 | 1.66 | 12.16 | -3.58 | 13.77 | -2.58 | 25.33 |
| Sino Biopharmaceutical Ltd | 29.55bn | 2.20bn | 63.14bn | 24.44k | 28.10 | 1.70 | 9.89 | 2.14 | 0.1196 | 0.2448 | 1.60 | 1.98 | 0.4050 | 2.37 | 3.74 | 1,145,223.00 | 7.42 | 13.11 | 14.50 | 21.74 | 82.92 | 80.37 | 18.33 | 27.47 | 1.07 | 11.10 | 0.1868 | 25.02 | 0.6657 | 4.63 | -10.29 | -27.22 | -7.18 | 1.15 |
| Innovent Biologics Inc | 8.22bn | -1.41bn | 69.48bn | 5.26k | -- | 5.06 | -- | 8.45 | -0.8857 | -0.8857 | 5.13 | 8.42 | 0.3905 | 1.32 | 6.25 | 1,688,010.00 | -6.71 | -13.06 | -8.22 | -15.85 | 82.44 | 84.51 | -17.18 | -43.44 | 2.51 | -3.68 | 0.2123 | -- | 36.21 | 265.79 | 52.83 | -- | 34.60 | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 04 Sep 2024 | 327.50m | 2.76% |
| First Sentier Investors (Hong Kong) Ltd.as of 31 May 2024 | 274.34m | 2.31% |
| First Sentier Investors (UK) IM Ltd.as of 31 May 2024 | 220.29m | 1.86% |
| UBS Asset Management Switzerland AGas of 13 Sep 2024 | 218.24m | 1.84% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 170.52m | 1.44% |
| Bosera Asset Management Co., Ltd.as of 31 Dec 2023 | 143.18m | 1.21% |
| BlackRock Fund Advisorsas of 28 Aug 2024 | 140.19m | 1.18% |
| Hang Seng Investment Management Ltd.as of 05 Sep 2024 | 138.95m | 1.17% |
| UBS Asset Management (Hong Kong) Ltd.as of 13 Sep 2024 | 112.15m | 0.95% |
| GF Fund Management Co., Ltd.as of 31 Dec 2023 | 110.81m | 0.93% |
